FDA's Buehler To Join Teva
This article was originally published in The Pink Sheet Daily
The former head of the Office of Generic Drugs will become Teva's VP of regulatory strategic operations.
You may also be interested in...
Outgoing Office of New Drugs director dismisses speculation that his decision to leave the agency was related to events surrounding Sarepta's controversial Exondys 51 approval.
Kathleen Uhl's five-month leave for cancer treatment ends as user fee negotiations move towards formal start.
Director Uhl’s medical leave puts bioequivalence office head John Peters in the limelight.